is bpc 157 approved in any country BPC-157 – No Proof Required! | Office for Science and Society BPC-157: Top Peptide for Injury
Description
He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, Li B
Likewise, remarkable safety (i.e., LD50 higher than 2000 mg/kg through oral or intravenous route in mice) confirmed no adverse effect in toxicology studies (none of the animals died)
For joint and tissue support, most users report significant improvements within 24 weeks
The results can be long-lasting, especially as the therapy helps your body return to better function
Suitable for multi-dose vial use
So, while BPC-157 is certainly not a GLP-1 agonist, both represent the incredible potential of peptide-based research
